Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812]
对“基于病理反应的新辅助帕博利珠单抗治疗可切除 III/IV 期皮肤黑色素瘤患者的长期疗效”的更正:[肿瘤学年鉴 34 (2023) 806-812]
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2024.03.002
Sharon, C E; Tortorello, G N; Ma, K L; Huang, A C; Xu, X; Giles, L R; McGettigan, S; Kreider, K; Schuchter, L M; Mathew, A J; Amaravadi, R K; Gimotty, P A; Miura, J T; Karakousis, G C; Mitchell, T C